RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SK Biopharmaceuticals Co Stock

SK Biopharmaceuticals Co P/S 2024

SK Biopharmaceuticals Co P/S

12.97

Ticker

326030.KS

ISIN

KR7326030004

As of Sep 29, 2024, SK Biopharmaceuticals Co's P/S ratio stood at 12.97, a -21.3% change from the 16.48 P/S ratio recorded in the previous year.

The SK Biopharmaceuticals Co P/S history

SK Biopharmaceuticals Co Aktienanalyse

What does SK Biopharmaceuticals Co do?

SK Biopharmaceuticals Co Ltd is a leading bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in South Korea and has been listed on the Korean Stock Exchange since 2014. The history of SK Biopharmaceuticals dates back to 1998 when it was established as a joint venture between SK Group and Hanmi Pharmaceutical. SK Biopharmaceuticals works closely with its parent companies, utilizing their extensive experience and infrastructure in research and development, production, and marketing. The business model of SK Biopharmaceuticals is based on creating value through research and development of drugs for the global market. Within this framework, the company develops innovative bio-pharmaceutical solutions for a range of therapeutic areas, particularly CNS disorders. SK Biopharmaceuticals strives to establish a strong presence in the global bio-pharmaceutical market through partnerships and strategic alliances with other companies. SK Biopharmaceuticals is organized into various divisions, including research and development, production, sales, and marketing. Each of these divisions is tailored to meet the needs of customers and patients to ensure optimal access to medications. The company has various products with different indications on the market worldwide, including the anticonvulsant Brivaracetam, which is approved for the treatment of epilepsy. Brivaracetam is a fast-acting, highly selective, and potent anticonvulsant that demonstrates significant reduction in seizure frequency in patients with epilepsy. SK Biopharmaceuticals continuously works to expand its product portfolio and develop innovative solutions for the treatment of neurological disorders. In addition to drug development for the global market, SK Biopharmaceuticals is also active in the field of biotechnology. The company is committed to harnessing the latest advancements in biotechnology and genomics to support the discovery, development, and commercialization of medications. SK Biopharmaceuticals has established itself as a leading company in the bio-pharmaceutical industry. The company is dedicated to excellence in research, development, and marketing of innovative solutions for the treatment of neurological disorders. With a strong global presence and a dedicated workforce, SK Biopharmaceuticals is well-positioned to further expand its position as a pioneer in the bio-pharmaceutical industry. SK Biopharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding SK Biopharmaceuticals Co's P/S Ratio

SK Biopharmaceuticals Co's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing SK Biopharmaceuticals Co's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating SK Biopharmaceuticals Co's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in SK Biopharmaceuticals Co’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about SK Biopharmaceuticals Co stock

What is the price-to-earnings ratio of SK Biopharmaceuticals Co?

The price-earnings ratio of SK Biopharmaceuticals Co is currently 12.97.

How has the price-earnings ratio of SK Biopharmaceuticals Co changed compared to last year?

The price-to-earnings ratio of SK Biopharmaceuticals Co has increased by -21.3% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of SK Biopharmaceuticals Co high compared to other companies?

Yes, the price-to-earnings ratio of SK Biopharmaceuticals Co is high compared to other companies.

How does an increase in the price-earnings ratio of SK Biopharmaceuticals Co affect the company?

An increase in the price-earnings ratio of SK Biopharmaceuticals Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of SK Biopharmaceuticals Co affect the company?

A decrease in the price-earnings ratio of SK Biopharmaceuticals Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of SK Biopharmaceuticals Co?

Some factors that influence the price-earnings ratio of SK Biopharmaceuticals Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does SK Biopharmaceuticals Co pay?

Over the past 12 months, SK Biopharmaceuticals Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SK Biopharmaceuticals Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of SK Biopharmaceuticals Co?

The current dividend yield of SK Biopharmaceuticals Co is .

When does SK Biopharmaceuticals Co pay dividends?

SK Biopharmaceuticals Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SK Biopharmaceuticals Co?

SK Biopharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of SK Biopharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is SK Biopharmaceuticals Co located?

SK Biopharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SK Biopharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SK Biopharmaceuticals Co from 9/29/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did SK Biopharmaceuticals Co pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of SK Biopharmaceuticals Co in the year 2023?

In the year 2023, SK Biopharmaceuticals Co distributed 0 KRW as dividends.

In which currency does SK Biopharmaceuticals Co pay out the dividend?

The dividends of SK Biopharmaceuticals Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SK Biopharmaceuticals Co

Our stock analysis for SK Biopharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Biopharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.